Efficacy and adverse effects of low-dose nateglinide in early type 2 diabetes: comparison with acarbose in a crossover study
- 90 Downloads
Recent studies have suggested that treatment of type 2 diabetes soon after diagnosis of diabetes correlates with a long-term reduction in the risk of macroangiopathy. An open-label prospective crossover trial was performed to compare the efficacy and adverse effects of low-dose nateglinide with those of acarbose. The subjects were 23 early type 2 Japanese diabetic patients who were oral hypoglycemic agent naïve and whose HbA1C levels were 6.0–6.9%. Twelve patients received 90 mg/day of nateglinide and 11 patients received 150 mg/day of acarbose. After 12 weeks of either therapy, the drugs were switched and treatment was continued for another 12 weeks. Each patient was requested to complete a questionnaire on complications after the completion of each treatment. HbA1C decreased from a mean baseline of 6.7 ± 0.2 to 6.4 ± 0.3% with nateglinide and to 6.5 ± 0.3% with acarbose. Decreases of HbA1C in nateglinide were larger than those in acarbose, albeit statistically insignificant (p = 0.073). Symptoms related to hypoglycemia were scarcely observed with either treatment. Abdominal fullness/borborygmi were frequently reported by patients on acarbose but were absent or mild in those on nateglinide. After the completion of the study, most patients favored nateglinide over acarbose. Our results suggest that the effects of low-dose nateglinide on postprandial hyperglycemia of early type 2 diabetes are equivalent to those of acarbose, with the added advantage of minimal side effects.
KeywordsPostprandial hyperglycemia Glinide Alpha-glucosidase inhibitor Hypoglycemia Adverse effects
Conflict of interest
This clinical trial received financial support from Daiichi Sankyo. Daiichi Sankyo did not have any influence on the analysis and interpretation of the data. T. Hirose, Y. Fujitani and R. Kawamori have received grant support from Takeda. RK, HW, and TH have also acted as spokespeople for Daiichi Sankyo. RK has received grant support from Nippon Eli Lilly. All of the other authors declare no conflict of interest.
- 7.Califf RM, Boolell M, Haffner SM, Bethel MA, McMurray J, Duggal A, et al. Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance rationale and design of the nateglinice and valsartan in impaired glucose tolerance outcomes research (NAVIGATOR) Trial. Am Heart J. 2008;156:623–32.CrossRefPubMedGoogle Scholar
- 12.Uchino H, Niwa M, Shimizu T, Nishiyama K, Kawamori R. Impairment of early insulin response after glucose load, rather than insulin resistance, is responsible for postprandial hyperglycemia seen in obese type 2 diabetes: assessment using nateglinide, a new insulin secretagogue. Endocr J. 2000;47:639–41.CrossRefPubMedGoogle Scholar
- 16.Skyler JS, Bergenstal R, Bonow RO, Buse J, Deedwania P, Gale EAM, et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care. 2009;32:187–92.CrossRefPubMedGoogle Scholar
- 17.The Diabetes Control Complication Trial/Epidemiology of Diabetes Interventions, Complications Research Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA. 2003;290:2159–67.CrossRefGoogle Scholar
- 26.Scorpiglione N, Belfiglio M, Carinci F, Cavaliere D, De Curtis A, Franciosi M, et al. The effectiveness, safety and epidemiology of the use of acarbose in the treatment of patients with type 2 diabetes mellitus. A model of medicine-based evidence. Eur J Clin Pharmacol. 1999;55:239–49.CrossRefPubMedGoogle Scholar